The genetic exclusivity and enhanced response of IDH1-mutant THP1 cells and primary AML specimens to IACS-010759, compared to IDH2-mutant cells, together provide a strong rationale for IACS-010759 as a tailored therapy for the IDH1-mutant subtype of AML. Here, IDH1 is linked to acute myeloid leukemia.